Povorcitinib beneficial for moderate-to-severe hidradenitis suppurativa
For patients with moderate-to-severe hidradenitis suppurativa (HS), povorcitinib (an oral Janus kinase 1 inhibitor) is beneficial, according to a study published online July 23 in Nature Medicine.